PRODUCT CODE: ER1706-32

TNFAIP3 Antibody (ER1706-32)

Applications

  • WB

  • ICC

  • IHC-P

  • FC

REACTIVITY

  • Human

  • Mouse

  • Rat

Western blot analysis of TNFAIP3 on Jurkat (1) and Daudi (2) cell lysate using anti-TNFAIP3 antibody at 1/100 dilution.
  • Western blot analysis of TNFAIP3 on Jurkat (1) and Daudi (2) cell lysate using anti-TNFAIP3 antibody at 1/100 dilution.
  • ICC staining TNFAIP3 in A431 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
  • ICC staining TNFAIP3 in LOVO cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
  • Immunohistochemical analysis of paraffin-embedded rat lung tissue using anti-TNFAIP3 antibody. Counter stained with hematoxylin.
  • Immunohistochemical analysis of paraffin-embedded human kidney tissue using anti-TNFAIP3 antibody. Counter stained with hematoxylin.
  • Immunohistochemical analysis of paraffin-embedded human kidney tissue using anti-TNFAIP3 antibody. Counter stained with hematoxylin.
  • Immunohistochemical analysis of paraffin-embedded mouse testis tissue using anti-TNFAIP3 antibody. Counter stained with hematoxylin.
  • Flow cytometric analysis of HepG2 cells with TNFAIP3 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black). Goat anti rabbit IgG (FITC) was used as the secondary antibody.
Western blot analysis of TNFAIP3 on Jurkat (1) and Daudi (2) cell lysate using anti-TNFAIP3 antibody at 1/100 dilution.

Applications

  • WB

  • ICC

  • IHC-P

  • FC

REACTIVITY

  • Human

  • Mouse

  • Rat

SPECIFICATIONS

Product Type

Rabbit polyclonal primary

Product Name

TNFAIP3 Antibody (ER1706-32)

Immunogen

Recombinant protein

Host

Rabbit

Positive Control

Jurkat, Daudi, A431, LOVO, rat lung tissue, human liver cancer tissue, human kidney tissue, mouse testis tissue, HepG2.

Conjugation

Unconjugated

Clonality

Polyclonal

PROPERTIES

Form

Liquid

Storage Condition

Store at +4C after thawing. Aliquot store at -20C or -80C. Avoid repeated freeze / thaw cycles.

Storage Buffer

1*PBS (pH7.4), 0.2% BSA, 50% Glycerol. Preservative: 0.05% Sodium Azide.

Concentration

1 ug/ul

PURIFICATION

Protein A purified.

MOLECULAR WEIGHT

90 kDa

Isotype

IgG

APPLICATION DILUTION

  • WB

  • 1:500

  • ICC

  • 1:100-1:500

  • IHC-P

  • 1:50-1:200

  • FC

  • 1:50-1:100

TARGET

UNIPROT #

PROTEIN NAME

Tumor necrosis factor alpha-induced protein 3

GENE NAME

TNFAIP3

SYNONYMS

TNF alpha-induced protein 3, TNFAIP3, OTUD7C

SEQUENCE SIMILARITIES

Belongs to the peptidase C64 family.

POST-TRANSLATIONAL MODIFICATION

Proteolytically cleaved by MALT1 upon TCR stimulation; disrupts NF-kappa-B inhibitory function and results in increased IL-2 production. It is proposed that only a fraction of TNFAIP3 colocalized with TCR and CBM complex is cleaved, leaving the main TNFAIP3 pool intact.

SUBCELLULAR LOCATION

Cytoplasm. Nucleus. Lysosome.; [A20p50]: Cytoplasm.

FUNCTION

Ubiquitin-editing enzyme that contains both ubiquitin ligase and deubiquitinase activities. Involved in immune and inflammatory responses signaled by cytokines, such as TNF-alpha and IL-1 beta, or pathogens via Toll-like receptors (TLRs) through terminating NF-kappa-B activity. Essential component of a ubiquitin-editing protein complex, comprising also RNF11, ITCH and TAX1BP1, that ensures the transient nature of inflammatory signaling pathways. In cooperation with TAX1BP1 promotes disassembly of E2-E3 ubiquitin protein ligase complexes in IL-1R and TNFR-1 pathways; affected are at least E3 ligases TRAF6, TRAF2 and BIRC2, and E2 ubiquitin-conjugating enzymes UBE2N and UBE2D3. In cooperation with TAX1BP1 promotes ubiquitination of UBE2N and proteasomal degradation of UBE2N and UBE2D3. Upon TNF stimulation, deubiquitinates 'Lys-63'-polyubiquitin chains on RIPK1 and catalyzes the formation of 'Lys-48'-polyubiquitin chains. This leads to RIPK1 proteasomal degradation and consequently termination of the TNF- or LPS-mediated activation of NF-kappa-B. Deubiquitinates TRAF6 probably acting on 'Lys-63'-linked polyubiquitin. Upon T-cell receptor (TCR)-mediated T-cell activation, deubiquitinates 'Lys-63'-polyubiquitin chains on MALT1 thereby mediating disassociation of the CBM (CARD11:BCL10:MALT1) and IKK complexes and preventing sustained IKK activation. Deubiquitinates NEMO/IKBKG; the function is facilitated by TNIP1 and leads to inhibition of NF-kappa-B activation. Upon stimulation by bacterial peptidoglycans, probably deubiquitinates RIPK2. Can also inhibit I-kappa-B-kinase (IKK) through a non-catalytic mechanism which involves polyubiquitin; polyubiquitin promotes association with IKBKG and prevents IKK MAP3K7-mediated phosphorylation. Targets TRAF2 for lysosomal degradation. In vitro able to deubiquitinate 'Lys-11'-, 'Lys-48'- and 'Lys-63' polyubiquitin chains. Inhibitor of programmed cell death. Has a role in the function of the lymphoid system. Required for LPS-induced production of proinflammatory cytokines and IFN beta in LPS-tolerized macrophages.